gefitinib has been researched along with maytansine in 2 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (maytansine) | Trials (maytansine) | Recent Studies (post-2010) (maytansine) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 815 | 96 | 592 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alfieri, RR; Ampollini, L; Ardizzoni, A; Bonelli, M; Caffarra, C; Cavazzoni, A; Cretella, D; Frati, C; Fumarola, C; Galetti, M; La Monica, S; Lagrasta, C; Petronini, PG; Quaini, F; Saccani, F; Tiseo, M | 1 |
Cosmai, L; Gallieni, M; Porta, C | 1 |
1 review(s) available for gefitinib and maytansine
Article | Year |
---|---|
Renal toxicity of anticancer agents targeting HER2 and EGFR.
Topics: Acute Kidney Injury; Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Maytansine; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Renal Dialysis; Renal Insufficiency, Chronic; Trastuzumab | 2015 |
1 other study(ies) available for gefitinib and maytansine
Article | Year |
---|---|
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression; Humans; Immunoconjugates; Lung Neoplasms; Maytansine; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |